RJA
LCTX icon

Raymond James & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Raymond James & Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$21.2K Sell
23,437
-2,289
-9% -$2.12K ﹤0.01% 3942
2024
Q2 		$25.7K Buy
25,726
+5,539
+27% +$6.12K ﹤0.01% 3866
2024
Q1 		$29.9K Hold
20,187
– – ﹤0.01% 3844
2023
Q4 		$22K Sell
20,187
-3,582
-15% -$3.92K ﹤0.01% 3763
2023
Q3 		$28K Hold
23,769
– – ﹤0.01% 3710
2023
Q2 		$33.5K Buy
23,769
+2,596
+12% +$3.59K ﹤0.01% 3738
2023
Q1 		$31.8K Buy
21,173
+1,000
+5% +$1.4K ﹤0.01% 3768
2022
Q4 		$23.6K Sell
20,173
-942
-4% -$1.19K ﹤0.01% 3780
2022
Q3 		$24K Buy
21,115
+1,502
+8% +$2.21K ﹤0.01% 3781
2022
Q2 		$31K Hold
19,613
– – ﹤0.01% 3839
2022
Q1 		$30K Buy
19,613
+2,800
+17% +$4.34K ﹤0.01% 3961
2021
Q4 		$41K Hold
16,813
– – ﹤0.01% 3970
2021
Q3 		$42K Hold
16,813
– – ﹤0.01% 3930
2021
Q2 		$48K Sell
16,813
-44
-0.3% -$114 ﹤0.01% 3920
2021
Q1 		$40K Sell
16,857
-3,021
-15% -$7.25K ﹤0.01% 3868
2020
Q4 		$35K Buy
19,878
+8,600
+76% +$12K ﹤0.01% 3654
2020
Q3 		$11K Hold
11,278
– – ﹤0.01% 3540
2020
Q2 		$10K Hold
11,278
– – ﹤0.01% 3479
2020
Q1 		$9K Sell
11,278
-1,000
-8% -$996 ﹤0.01% 3446
2019
Q4 		$11K Buy
12,278
+65
+0.5% +$54 ﹤0.01% 3632
2019
Q3 		$12K Hold
12,213
– – ﹤0.01% 3557
2019
Q2 		$13K Buy
12,213
+39
+0.3% +$45 ﹤0.01% 3573
2019
Q1 		$16K Buy
+12,174
New +$15.1K ﹤0.01% 3543
2017
Q2 		– Sell
-36,507
Closed -$110K – 3396
2017
Q1 		$110K Buy
+36,507
New +$104K ﹤0.01% 3059

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James & Associates's LCTX Position: Q3 2024 in Review

Raymond James & Associates reduced its Lineage Cell Therapeutics (LCTX) stake by 8.9% in Q3 2024, selling an estimated $2.12K and leaving 23,437 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3942.

Raymond James & Associates first reported a position in LCTX in Q1 2017 and has held it in 24 quarters since. The position peaked at $110K in Q1 2017. 114 funds tracked by Wall St. Rank hold LCTX as of Q3 2024.

  • Raymond James & Associates held 23,437 shares of Lineage Cell Therapeutics worth $21.2K as of Q3 2024.
  • Raymond James & Associates sold 2,289 Lineage Cell Therapeutics shares in Q3 2024, an estimated $2.12K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3942 holding.
  • Raymond James & Associates first reported a position in Lineage Cell Therapeutics in Q1 2017 and has held it in 24 quarters since.
  • Raymond James & Associates's Lineage Cell Therapeutics position peaked at $110K in Q1 2017.
  • 114 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.